Pharmaceutical intermediates
Upadacitinib Intermediates
8 pharmaceutical intermediates for Upadacitinib. Indication: Arthritis; Ankylosing Spondylitis.
About Upadacitinib
- Originator
- AbbVie
- Indication
- Arthritis; Ankylosing Spondylitis
- Approved Date
- 08/16/2019
- DS/DP
- 01/15/2031
Available intermediates
8 intermediates currently listed for Upadacitinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate | 1201187-44-1 | / | / |
| (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester | 1428243-26-8 | / | / |
| N-[5-[(4-Methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]carbamic acid ethyl ester | 1869118-24-0 | / | / |
| N-Tosyl-5-bromo-4,7-diazaindole | 1201186-54-0 | / | / |
| 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid | 1869118-25-1 | / | / |
| (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid | 1428243-24-6 | / | / |
| 8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine | 1428243-28-0 | / | / |
| 5-Bromo-4,7-diazaindole | 875781-43-4 | / | / |
Other programs under U
Building toward Upadacitinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →